Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

EKF Diagnostics to Premier Novel Diagnostic Tests at Medica 2013

Published: Friday, November 08, 2013
Last Updated: Thursday, November 07, 2013
Bookmark and Share
Visit Medica 2013, Hall 3 Stand C70.

EKF Diagnostics has announced that it will be premiering two novel diagnostic tests at Medica 2013, 20th to 23rd November, Düsseldorf, Germany.

On Stand C70 in Hall 3, EKF will introduce an updated version of Lactate Scout+, a hand-held POC analyzer for the measurement of lactate.

This third version of Lactate Scout+ features hematocrit compensation which uniquely ensures that results from the analyzer are highly accurate, particularly in subjects with high concentrations of hematocrit such as elite athletes and neonates.

A second feature of the upgraded analyzer is that Lactate Scout+ now provides the fastest results (10 seconds) from the smallest sample of capillary blood (0.2 µL) of any competing device.

The second test to be introduced by EKF at Medica is a new test kit for Soluble Tumor Necrosis Factor receptor 1 (sTNFr1). sTNFr1 identifies diabetic patients at high risk of End Stage Renal Disease (ESRD), up to 10 years in advance.

Based on a standard ELISA, the test detects circulating levels of sTNFr1 in just a few hours. Early diagnosis of ESRD leads to improved patient outcomes and reduced healthcare costs.

The ELISA kit, which was developed in conjunction with the Joslin Diabetes Center in Boston, USA, is also available for sale.

EKF CEO, Julian Baines commented, “20 years after the onset of overt nephropathy, approximately 20% of diabetic patients will have progressed to ESRD. Our sTNFr1 assay will lead to improvements in the way patients are managed and reduce the burden on healthcare systems. We are confident that sTNFr1 will provide a step-change in the way ESRD is detected and managed and we are in the process of identifying accredited test labs in the USA to complement our work in Europe.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

EKF Diagnostics’ Growth Drives New Role Creation
Expanding business welcomes new faces to further strengthen IVD expertise and new product development.
Saturday, July 18, 2015
EKF Diagnostics Collaborates with Joslin Diabetes Center
Supporting the ongoing clinical and commercial development of early Diabetic Kidney Disease biomarkers.
Monday, November 17, 2014
Studies Validate EKF Diagnostics’ Early Stage Test for Progressive DKD
Independent scientific evidence confirms novel sTNFR1/2 biomarkers can accurately predict end-stage renal disease, up to 10 years in advance.
Friday, May 23, 2014
New Clinical Diagnostics Distributor Program Enhances EKF Customer Service
EKF Diagnostics appoints Simona Carnielli as new EMEA Distribution Manager.
Thursday, May 08, 2014
EKF Diagnostics Acquires Selah Genomics and DiaSpect Medical
Combined with the recent acquisition of Seperation Technology the purchases strengthen EKF’s product and services offering.
Tuesday, April 22, 2014
EKF Diagnostics Acquires Separation Technology
Acquisition complements EKF’s existing offering in the hemoglobin testing market place.
Thursday, March 27, 2014
PointMan™ Enriches Low-level DNA Mutations from Whole Blood
Ultra-sensitive PointMan™ enables blood sampling instead of tissue biopsies for cancer patient mutation status assessment.
Wednesday, January 22, 2014
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos